MX2020006237A - Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. - Google Patents

Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.

Info

Publication number
MX2020006237A
MX2020006237A MX2020006237A MX2020006237A MX2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
diseases related
dux4 expression
dux4
Prior art date
Application number
MX2020006237A
Other languages
English (en)
Inventor
Monika Ermann
Marcus Geese
Martin Schneider
Maeyer Joris De
Sebastian Monecke
Alexander Kaever
Timothy Robin James
Original Assignee
Facio Intellectual Property B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Facio Intellectual Property B V filed Critical Facio Intellectual Property B V
Publication of MX2020006237A publication Critical patent/MX2020006237A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos para el tratamiento de enfermedades relacionadas con la expresión de DUX4, tales como distrofias musculares. También se refiere al uso de tales compuestos, o a métodos de uso de tales compuestos.
MX2020006237A 2017-12-13 2018-12-13 Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. MX2020006237A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17207162 2017-12-13
PCT/EP2018/084802 WO2019115711A1 (en) 2017-12-13 2018-12-13 Compounds for treatment of diseases related to dux4 expression

Publications (1)

Publication Number Publication Date
MX2020006237A true MX2020006237A (es) 2020-11-06

Family

ID=60673528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006237A MX2020006237A (es) 2017-12-13 2018-12-13 Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.

Country Status (13)

Country Link
US (3) US10973820B2 (es)
EP (2) EP3498278B1 (es)
JP (1) JP2021506765A (es)
KR (1) KR20200098536A (es)
CN (1) CN111479570A (es)
AU (1) AU2018382974A1 (es)
CA (1) CA3083975A1 (es)
DK (1) DK3498278T3 (es)
ES (1) ES2791539T3 (es)
IL (1) IL275321A (es)
MX (1) MX2020006237A (es)
WO (1) WO2019115711A1 (es)
ZA (1) ZA202003407B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722513B2 (en) 2015-03-23 2020-07-28 The University Of Melbourne Treatment of respiratory diseases
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
EP3877382B1 (en) 2018-11-07 2026-03-18 Tianli Biotech Pty Ltd Novel compounds for the treatment of respiratory diseases
TW202112368A (zh) * 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
CA3159250A1 (en) * 2019-11-29 2021-06-03 Facio Intellectual Property B.V. New compounds for treatment of diseases related to dux4 expression
US20230271953A1 (en) * 2019-11-29 2023-08-31 Facio Intellectual Property B.V. Novel compounds for treatment of diseases related to DUX4 expression
CN115298183A (zh) * 2020-03-27 2022-11-04 北京原基华毅生物科技有限公司 作为酪蛋白激酶抑制剂的化合物
BR112022022437A2 (pt) 2020-05-07 2023-01-03 Adorx Therapeutics Ltd Antagonistas do receptor a2a de adenosina
AU2021342155A1 (en) 2020-09-11 2023-04-13 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
US20240076291A1 (en) * 2020-11-24 2024-03-07 Merck Sharp & Dohme Llc Modified isoindolinones as glucosylceramide synthase inhibitors
GB202019622D0 (en) * 2020-12-11 2021-01-27 Adorx Therapeutics Ltd Antagonist compounds
US20250275965A1 (en) * 2020-12-15 2025-09-04 Gritscience Biopharmaceuticals Co.,Ltd. Compounds as casein kinase inhibitors
WO2023241552A1 (en) * 2022-06-14 2023-12-21 Gritscience Biopharmaceuticals Co., Ltd Salt and/or crystal form for compounds as casein kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004020685D1 (de) 2003-12-11 2009-05-28 Aventis Pharma Inc Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
DK2493876T3 (en) 2009-10-28 2014-03-10 Pfizer Imidazole derivatives AS casein kinase inhibitors
HUE032405T2 (en) 2010-12-20 2017-09-28 Pfizer New condensed pyridine compounds as casein kinase inhibitors
EP2546357A1 (en) 2011-07-14 2013-01-16 Erasmus University Medical Center Rotterdam A new classifier for the molecular classification of multiple myeloma.
WO2014081923A1 (en) 2012-11-21 2014-05-30 The Johns Hopkins University Genomic classifiers for non-invasive identification of high grade prostate cancer with metastatic potential
ES2489297B1 (es) * 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
US9814728B2 (en) 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
AU2015212341A1 (en) * 2014-02-03 2016-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of Casein kinase I inhibitors for depleting stem cells
EP3102207B1 (en) 2014-02-07 2022-05-11 Agency For Science, Technology And Research 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
WO2015195880A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Imidazo-pyridazne derivatives as casein kinase 1 delta/epsilon inhibitors
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression

Also Published As

Publication number Publication date
CN111479570A (zh) 2020-07-31
US20190175596A1 (en) 2019-06-13
EP3498278A1 (en) 2019-06-19
IL275321A (en) 2020-07-30
EP3498278B1 (en) 2020-03-18
US10973820B2 (en) 2021-04-13
JP2021506765A (ja) 2021-02-22
EP3723756A1 (en) 2020-10-21
KR20200098536A (ko) 2020-08-20
ZA202003407B (en) 2022-06-29
US20210177847A1 (en) 2021-06-17
ES2791539T3 (es) 2020-11-04
DK3498278T3 (da) 2020-04-20
US20220226318A1 (en) 2022-07-21
WO2019115711A1 (en) 2019-06-20
CA3083975A1 (en) 2019-06-20
AU2018382974A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
SG10201811384TA (en) Mnk inhibitors and methods related thereto
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
NZ761519A (en) Nlrp3 modulators
MX370412B (es) Compuesto antimicotico.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016501613A1 (en) Pyrazines modulators of gpr6
PH12017501872A1 (en) Methods of treating diseases
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease